Objective To systematically consolidate the most consistently applicable risk factors and assess their predictive performance for gestational diabetes mellitus (GDM) prediction. Design Systematic ...
Correspondence to Dr Minna Johansson, General Practice, University of Gothenburg, Goteborg 45152, Sweden; minna.johansson{at}vgregion.se A companion project outlining the methods in more detail has ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
Correspondence to Dr Mohammad Hassan Murad, Evidence-Based Practice Center, Mayo Clinic, Rochester, MN 55905, USA; murad.mohammad{at}mayo.edu In 1904, Dr James Herrick evaluated a 20-year-old patient ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
Correspondence to Victoria Charlton, Global Health and Social Medicine, King's College London, London WC2R 2LS, UK; victoria.charlton{at}kcl.ac.uk In 2004, former BMJ editor Richard Smith described ...
Correspondence to Ms Meera Garriga, University of California San Francisco, San Francisco, CA 94143, USA; meera.garriga{at}ucsf.edu If you wish to reuse any or all of ...
The National Institute for Health and Care Excellence (NICE) has been presented as politically independent, asserting it is free from industry influence and conflicts of interest so that its decisions ...
Background and Objectives As teaching technology advances, medical education is increasingly using digital mediums and exploring instructional models such as the flipped classroom and blended learning ...
In 2023, the World Health Assembly adopted a resolution to strengthen rehabilitation within health systems, calling for ...
Background The adaptation of clinical practice guidelines (CPGs) is increasingly used to efficiently develop contextualised recommendations for local, regional and national settings. However, ...
Last 28 March 2025, the European Commission decided not to renew the conditional marketing authorisation for Translarna (ataluren) in Duchenne’s disease due to lack of efficacy after 11 years in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback